CDSCO approves Jardiance for treatment of adults with chronic kidney disease in India

Dr. Shraddha Bhure, Medical Director, Boehringer Ingelheim India, emphasized the significance of this development. “CKD is a major health problem in India, arising from common risk factors like diabetes, hypertension, or cardiovascular disease, to name a few. Patients with CKD progression are at increased risk of hospital admissions, cardiac events, kidney failure, and death. Apart from the impact on health, a large proportion of patients with CKD also need to face catastrophic health expenditures. The prognosis of CKD may vary according to different underlying causes and/or stages of CKD; this may necessitate proven treatment options for different patients with CKD. The scientific evidence with empagliflozin, on providing clinically meaningful improvement in CKD outcomes across a broad range of eligible patients, provides compelling reasons to improve the current treatment landscape of CKD. Optimum management of CKD can foster substantial improvements in the health and economic outcomes, for not only the patients and their families but also the society and the country’s healthcare system at large.”

Padma Shri Dr. (Prof.) Kamlakar Tripathi has quoted, “Chronic kidney disease has been recognized as a priority in our country’s national program for non-communicable diseases. In the early stages, chronic kidney disease often progresses without overt clinical symptoms, which often leads to a delay in the diagnosis. Patients who are diagnosed with advanced chronic kidney disease, are at much greater risk of major events like hospitalizations, kidney failure, and cardiovascular death. A key aspect of optimum kidney care is early detection and slowing the progression of chronic kidney disease. An early intervention can retard the progression towards end-stage kidney disease.”

“People with diabetes, high blood pressure, cardiovascular disease, and family history of kidney disease, are some individuals who have a high risk for developing chronic kidney disease. It is essential that these individuals get regularly tested for chronic kidney disease and receive appropriate treatment for optimum kidney protection. It is heartening that good scientific research, like the EMPA-KIDNEY study, is yielding promising treatment options that can serve more diverse groups of eligible patients with chronic kidney disease,” added Dr. Tripathi.